CIK 0001434316
- Non-accelerated filer
- Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 651311552
- Phone
- +1 858-875-1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-07-21 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −30,000 | 6,246 | ||
| 2022-07-07 | Valamehr Bahram Chief R&D Officer | Option exercise | +17,158 | $2.73 | $47K | 196,992 |
| 2022-07-07 | Valamehr Bahram Chief R&D Officer | Sale | −17,158 | $30.23 | $519K | 179,834 |
| 2022-07-07 | Valamehr Bahram Chief R&D Officer | Option exercise · Stock Option (Right to Buy) | −17,158 | $2.73 | $47K | 13,156 |
| 2022-07-06 | Valamehr Bahram Chief R&D Officer | Option exercise | +2,000 | $4.84 | $10K | 181,834 |
| 2022-07-06 | Valamehr Bahram Chief R&D Officer | Option exercise | +5,842 | $2.73 | $16K | 187,676 |
| 2022-07-06 | Valamehr Bahram Chief R&D Officer | Sale | −7,842 | $30.07 | $236K | 179,834 |
| 2022-07-06 | Valamehr Bahram Chief R&D Officer | Option exercise · Stock Option (Right to Buy) | −2,000 | $4.84 | $10K | 8,704 |
| 2022-07-06 | Valamehr Bahram Chief R&D Officer | Option exercise · Stock Option (Right to Buy) | −5,842 | $2.73 | $16K | 30,314 |
| 2022-07-05 | Plavsic Mark Chief Technical Officer | Sale | −3,719 | $24.61 | $92K | 127,123 |
| 2022-06-27 | Powl Brian T. Chief Commercial Officer | Grant or award | +45,000 | 45,000 | ||
| 2022-06-27 | Powl Brian T. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2022-06-09 | Xu Yuan Director | Grant or award | +8,650 | 13,394 | ||
| 2022-06-09 | Xu Yuan Director | Grant or award · Stock Option (Right to Buy) | +11,893 | 11,893 | ||
| 2022-06-09 | RASTETTER WILLIAM H Director | Grant or award | +8,650 | 11,331 | ||
| 2022-06-09 | RASTETTER WILLIAM H Director | Grant or award · Stock Option (Right to Buy) | +11,893 | 11,893 | ||
| 2022-06-09 | MENDLEIN JOHN Director | Grant or award | +8,650 | 166,741 | ||
| 2022-06-09 | MENDLEIN JOHN Director | Grant or award · Stock Option (Right to Buy) | +11,893 | 11,893 | ||
| 2022-06-09 | Jooss Karin Director | Grant or award | +8,650 | 9,848 | ||
| 2022-06-09 | Jooss Karin Director | Grant or award · Stock Option (Right to Buy) | +11,893 | 11,893 |
Page 9 of 26 · 503 trades